In This Article:
Ocular Therapeutix (NASDAQ:OCUL) First Quarter 2025 Results
Key Financial Results
-
Revenue: US$10.7m (down 28% from 1Q 2024).
-
Net loss: US$64.1m (loss narrowed by 1.2% from 1Q 2024).
-
US$0.38 loss per share (improved from US$0.49 loss in 1Q 2024).
We've discovered 3 warning signs about Ocular Therapeutix. View them for free.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Ocular Therapeutix Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 37%. Earnings per share (EPS) also missed analyst estimates by 29%.
Looking ahead, revenue is forecast to grow 49% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 4.9% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for Ocular Therapeutix that you should be aware of before investing here.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.